Long-Term Outcomes of Topical 5% Imiquimod Treatment for Lentigo Maligna: A Systematic Review.

ABSTRACT:

Introduction

Lentigo maligna (LM) is a melanoma in situ frequently located on sun-exposed areas. While surgery is the standard of care, topical 5% imiquimod has emerged as a non-invasive alternative for patients unsuitable for surgery. However, existing literature often lacks long-term follow-up. This systematic review aims to assess the long-term effectiveness and safety of imiquimod in LM, focusing on studies with ≥ 48 months of follow-up.

Methods

A comprehensive search was conducted in MEDLINE (PubMed) and the Cochrane Library up to July 2025. Inclusion criteria comprised original studies reporting on LM treated with 5% imiquimod with ≥ 48 months of follow-up.

Results

Six studies (422 patients) met the inclusion criteria: one prospective and five retrospective stud

SUBMITTER: Balado-Simo P 

PROVIDER: S-EPMC12619878 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature